Literature DB >> 26739034

Changes in plasma phosphate during in-patient treatment of children with severe acute malnutrition: an observational study in Uganda.

Hanifa Namusoke1, Anne-Louise Hother2, Maren Jh Rytter2, Pernille Kæstel2, Esther Babirekere-Iriso3, Christian Fabiansen2, Tsinuel Girma4, Christian Ritz2, Kim F Michaelsen2, André Briend5, Henrik Friis6.   

Abstract

BACKGROUND: Children treated for severe acute malnutrition (SAM) are at risk of refeeding hypophosphatemia. Therapeutic diets have only recently become fortified with phosphorus to meet United Nations (UN) specifications, but to our knowledge no studies have investigated the effect.
OBJECTIVE: The aim was to assess concentrations and correlates of plasma phosphate (P-phosphate) at admission and during treatment and to identify correlates of changes in P-phosphate.
DESIGN: This was a prospective observational study in 6- to 59-mo-old children admitted for treatment of SAM to Mulago Hospital, Uganda. P-phosphate was measured at admission, on the second day of treatment with a therapeutic formula containing 75 kcal/100 mL and 560 mg phosphorus/L (F-75, Nutriset), at the start of the transition to a therapeutic formula containing 100 kcal/100 mL and 579 mg phosphorus/L (F-100; Nutriset), at day 2 of transition, and at discharge.
RESULTS: Among 120 children, mean ± SD P-phosphate at admission was 1.04 ± 0.31 mmol/L and increased by 0.43 (95% CI: 0.35, 0.52) mmol/L during the first 2 d and more slowly toward discharge. Most (79%) children experienced their lowest P-phosphate concentration at admission, and none developed severe hypophosphatemia. P-phosphate was lowest in children with edema and with elevated C-reactive protein, and a lower increase was seen with increasing caretaker-reported severity of illness. Partially or fully replacing F-75 with rice porridge (i.e., a local practice to reduce diarrhea) during the first 2 d of stabilization was associated with a 0.34-mmol/L (95% CI: 0.18, 0.50 mmol/L) lower increase in P-phosphate during the same first 2 d.
CONCLUSIONS: F-75, which complies with UN specifications and provides 73 mg phosphorus · kg(-1) · d(-1) (130 mL · kg(-1) · d(-1)), seems to prevent refeeding hypophosphatemia in children with SAM. Replacing this formula with rice porridge during the first days of treatment to manage diarrhea may have an adverse effect on P-phosphate concentrations. This study was registered at http://www.isrctn.com as ISRCTN55092738.
© 2016 American Society for Nutrition.

Entities:  

Keywords:  Africa; children; diarrhea; hypophosphatemia; phosphorus; refeeding syndrome; rice porridge; severe acute malnutrition; therapeutic feeding

Mesh:

Substances:

Year:  2016        PMID: 26739034     DOI: 10.3945/ajcn.115.117374

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  3 in total

1.  Changes in serum phosphate and potassium and their effects on mortality in malnourished African HIV-infected adults starting antiretroviral therapy and given vitamins and minerals in lipid-based nutritional supplements: secondary analysis from the Nutritional Support for African Adults Starting Antiretroviral Therapy (NUSTART) trial.

Authors:  Andrea Mary Rehman; Susannah Louise Woodd; Douglas Corbett Heimburger; John Robert Koethe; Henrik Friis; George PrayGod; Lackson Kasonka; Paul Kelly; Suzanne Filteau
Journal:  Br J Nutr       Date:  2017-04-10       Impact factor: 3.718

2.  Transition from F-75 to ready-to-use therapeutic food in children with severe acute malnutrition, an observational study in Uganda.

Authors:  Betty Lanyero; Hanifa Namusoke; Nicolette Nabukeera-Barungi; Benedikte Grenov; Ezekiel Mupere; Kim Fleischer Michaelsen; Christian Mølgaard; Vibeke Brix Christensen; Henrik Friis; André Briend
Journal:  Nutr J       Date:  2017-08-30       Impact factor: 3.271

3.  Correlates of thymus size and changes during treatment of children with severe acute malnutrition: a cohort study.

Authors:  Maren Johanne Heilskov Rytter; Hanifa Namusoke; Christian Ritz; Kim F Michaelsen; André Briend; Henrik Friis; Dorthe Jeppesen
Journal:  BMC Pediatr       Date:  2017-03-14       Impact factor: 2.125

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.